Literature DB >> 14976600

Toll-like receptor 4 is critical to innate host defense in a murine model of bordetellosis.

Paul B Mann1, Mary J Kennett, Eric T Harvill.   

Abstract

Bordetellae are important respiratory pathogens that cause pertussis (whooping cough) in humans and analogous diseases in domestic and wild animals. Immunity to Bordetella is poorly understood, in particular the early innate immune responses that contribute to inflammation, pathology, and the subsequent generation of adaptive immunity. Using B. bronchiseptica, which naturally infects mice, we show that Toll-like receptor-4 (TLR4) is required for cytokine responses to this pathogen's lipopolysaccharide (LPS) and that TLR4 deficiency results in impaired cytokine responses in vitro and in vivo. TLR4-deficient mice rapidly succumb following inoculation with as few as 1000 organisms, indicating that TLR4 is critical to innate host defense against bordetellosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14976600     DOI: 10.1086/381898

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  31 in total

1.  Contribution of Bordetella filamentous hemagglutinin and adenylate cyclase toxin to suppression and evasion of interleukin-17-mediated inflammation.

Authors:  Michael W Henderson; Carol S Inatsuka; Amanda J Sheets; Corinne L Williams; David J Benaron; Gina M Donato; Mary C Gray; Erik L Hewlett; Peggy A Cotter
Journal:  Infect Immun       Date:  2012-04-02       Impact factor: 3.441

2.  Toll-like receptor 4-dependent early elicited tumor necrosis factor alpha expression is critical for innate host defense against Bordetella bronchiseptica.

Authors:  Paul B Mann; Kelly D Elder; Mary J Kennett; Eric T Harvill
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

3.  Host genetics of Bordetella pertussis infection in mice: significance of Toll-like receptor 4 in genetic susceptibility and pathobiology.

Authors:  H A Banus; R J Vandebriel; H de Ruiter; J A M A Dormans; N J Nagelkerke; F R Mooi; B Hoebee; H J van Kranen; T G Kimman
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

4.  Toll-like receptor 4 contributes to colitis development but not to host defense during Citrobacter rodentium infection in mice.

Authors:  Mohammed A Khan; Caixia Ma; Leigh A Knodler; Yanet Valdez; Carrie M Rosenberger; Wanyin Deng; B Brett Finlay; Bruce A Vallance
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

5.  Use of a genetically defined double mutant strain of Bordetella bronchiseptica lacking adenylate cyclase and type III secretion as a live vaccine.

Authors:  Paul Mann; Elizabeth Goebel; James Barbarich; Mylisa Pilione; Mary Kennett; Eric Harvill
Journal:  Infect Immun       Date:  2007-04-23       Impact factor: 3.441

6.  Replacement of adenylate cyclase toxin in a lineage of Bordetella bronchiseptica.

Authors:  Anne M Buboltz; Tracy L Nicholson; Mylisa R Parette; Sara E Hester; Julian Parkhill; Eric T Harvill
Journal:  J Bacteriol       Date:  2008-06-13       Impact factor: 3.490

7.  Comparative toll-like receptor 4-mediated innate host defense to Bordetella infection.

Authors:  Paul B Mann; Daniel Wolfe; Eicke Latz; Douglas Golenbock; Andrew Preston; Eric T Harvill
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

8.  Role of pagL and lpxO in Bordetella bronchiseptica lipid A biosynthesis.

Authors:  I MacArthur; J W Jones; D R Goodlett; R K Ernst; A Preston
Journal:  J Bacteriol       Date:  2011-07-15       Impact factor: 3.490

9.  A critical role for the TLR signaling adapter Mal in alveolar macrophage-mediated protection against Bordetella pertussis.

Authors:  N J Bernard; C M Finlay; G M Tannahill; J P Cassidy; L A O'Neill; K H G Mills
Journal:  Mucosal Immunol       Date:  2014-12-17       Impact factor: 7.313

10.  Control of Pseudomonas aeruginosa in the lung requires the recognition of either lipopolysaccharide or flagellin.

Authors:  Reuben Ramphal; Viviane Balloy; Jeevan Jyot; Amrisha Verma; Mustapha Si-Tahar; Michel Chignard
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.